Richard Brundage

Dr. Richard Brundage

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2007 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
WBWonkyung Byon
Wonkyung Byon
CFCourtney V. Fletcher
Courtney V. Fletcher
RBRichard Brundage
Richard Brundage

1 December 2005 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
JAJae Eun Ahn
Jae Eun Ahn
ABAngela K. Birnbaum
Angela K. Birnbaum
RBRichard Brundage
Richard Brundage

1 January 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ASAhmed Hamed Salem
Ahmed Hamed Salem
CFCourtney V. Fletcher
Courtney V. Fletcher
RBRichard Brundage
Richard Brundage
The aim of this analysis was to create a pharmacometric model of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. The data consisted of 3,172 plasma concentrations from 96 HIV-1-infected children who participated in the Pediatric AIDS Clinical Trials Group 382 (PACTG382) study. Analyses were performed using NONMEM, and the impacts of body weight, age, race, sex, formulation, liver function, and cytochrome P450 2B6 (CYP2B6)-G516T and multidrug-resistance transporter gene (MDR1)-C3435T polymorphisms were assessed. A one-compartment model using weight-based allometry on oral clearance and apparent volume of distribution adequately described the data. A sigmoid maximum-effect (Emax) maturation model demonstrated an increase in oral clearance with age to reach 90% of its mature level by the age of 9 months. The liquid formulation bioavailability relative to the capsule was found to increase with age to reach 90% of its mature value by the age of 8 years. The CYP2B6-G516T polymorphism decreased oral clearance, while the MDR1-C3435T polymorphism demonstrated no effect.

12 January 2018 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MOMalek Okour
Malek Okour
PJPamala A. Jacobson
Pamala A. Jacobson
MAMariam A. Ahmed
Mariam A. Ahmed
AIAjay K. Israni
Ajay K. Israni
RBRichard Brundage
Richard Brundage

22 July 2017 in Current Pharmacology Reports
Verified
Journal Article
Closed access
PDF file
MOMalek Okour
Malek Okour
RBRichard Brundage
Richard Brundage

26 July 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
MAMariam A. Ahmed
Mariam A. Ahmed
MJMutaz Jaber
Mutaz Jaber
TTThang N. Tran
Thang N. Tran
BWBrian A. Willis
Brian A. Willis
KSKyriakie Sarafoglou
Kyriakie Sarafoglou
Aims: The aim of this study was to characterize the pharmacokinetic/pharmacodynamic relationships of cortisol and the adrenal biomarkers 17‐hydroxyprogesterone and androstenedione in children with congenital adrenal hyperplasia (CAH).Methods: A nonlinear mixed‐effect modelling approach was used to analyse cortisol, 17‐hydroxyprogesterone and androstenedione concentrations obtained over 6 hours from children with CAH (n = 50). A circadian rhythm was evident and the model leveraged literature information on circadian rhythm in untreated children with CAH. Indirect response models were applied in which cortisol inhibited the production rate of all three compounds using an Imax model.Results: Cortisol was characterized by a one‐compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively. The IC50 values of cortisol concentrations for cortisol, 17‐hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively. The inhibitory effect was found to be more potent on 17OHP than D4A, and the IC50 values were higher in salt‐wasting subjects than simple virilizers. Production rates of cortisol, 17‐hydroxyprogesterone and androstenedione were higher in simple‐virilizer subjects. Half‐lives of cortisol, 17‐hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.Conclusion: Rapidly changing biomarker responses to cortisol concentrations highlight that single measurements provide volatile information about a child's disease control. Our model closely captured observed cortisol, 17‐hydroxyprogesterone and androstenedione concentrations. It can be used to predict concentrations over 24 hours and allows many novel exposure metrics to be calculated, e.g., AUC, AUC‐above‐threshold, time‐within‐range, etc. Our long‐range goal is to uncover dose–exposure–outcome relationships that clinicians can use in adjusting hydrocortisone dose and timing.